New avenues for identifying and evaluating treatments for CDKL5 deficiency disorder
Researchers from the Institute for Bioengineering of Catalonia (IBEC) have participated in a study led by Imperial College London in which the role of cyclin-dependent protein kinase 5 (CDKL5) in pain perception has been uncovered.
The defective version of the gene that produces this protein is behind CDKL5 deficiency disorder, a rare disease with no cure for which effective treatments will now be testable in mouse model, thanks to the results of this work.
Researchers from the Institute for Bioengineering of Catalonia (IBEC) have participated in a study led by Imperial College London in which the role of cyclin-dependent protein kinase 5 (CDKL5) in pain perception has been uncovered.
Experts in bioengineering and informatics, including IBEC´s Associated Researcher Maria-Pau Ginebra, have published a paper where the researchers propose the creation of tools based on Artificial Intelligence for the development of biomaterials in Nature Reviews Materials.
An international team, led by Profs Giuseppe Battaglia and Loris Rizzello from the Institute for Bioengineering of Catalonia (IBEC), carried out out a study that opens the door to a new therapy capable of quickly and effectively eliminating infections caused by intracellular bacteria, the most resistant to immune defenses.
IBEC researchers develop new multi-responsive molecules able to self-assemble in water forming fiber-like structures. The so-called discotic molecules show responsiveness to temperature, light, pH, and ionic strength and they might show great potential for medical applications such as drug delivery systems, diagnosis or tissue engineering.
An international group of researchers from the University of Maryland (United States) and the Institute for Bioengineering of Catalonia (IBEC) led by ICREA Research Professor Silvia Muro, has identified a new way of transporting drugs to the brain, one of the major challenges of the pharmaceutical science today, that could help to come up with new treatments for neurological diseases such as Parkinson’s or Alzheimer’s.
Xavier Trepat, group leader of the “Integrative cell and tissue dynamics” at IBEC together with Raimon Sunyer, Senior researcher in Trepat’s lab, have written a Primer in Current Biology magazine on “Durotaxis”, a cell migration mechanism that might have a role in several disease states that include the stiffening of tissues.